Our mission is to harness the great promise offered by stem cell technology towards the treatment, and possibly cure, of a broad array of intractable human disease for the benefit of patients, family members, physicians and society in general.
|
|
|
StemCells, Inc. is focused on the development and commercialization of cell-based technologies. Our therapeutic product development programs target diseases of the central nervous system (CNS) and Liver.
We are a world leader in the discovery and development of human neural stem cell technology.
Our lead product candidate, HuCNS-SCŪ cells (purified human neural stem cells), is in clinical development for the treatment
of two fatal neurodegenerative disorders that primarily affect young children.
|
We also market specialty cell culture media products under the brand SC Proven®, and are developing our cell-based technologies for use in drug discovery and development.
Our strong intellectual property position includes exclusive rights to approximately 55 issued or allowed U.S. patents and approximately 200 granted or allowed non-U.S. patents.
Our scientific founders, who are also members of our Scientific Advisory Board, are recognized as world leaders in stem cell biology.
|
Stem Cell Sciences Acquisition
In April 2009, we acquired the operations of Stem Cell Sciences plc. This acquisition solidifies our leadership position in human neural stem cell technology, broadens our proprietary cell-based technologies, adds expertise and infrastructure for providing cell-based assays for drug discovery and screening, adds a revenue-generating cell culture media business, and establishes a European presence with operations in Cambridge, U.K.
Read more about the acquisition.
Visit Stem Cell Sciences. |
|
|
